

ZIOPHARM ONCOLOGY INC
 Form 3
 February 17, 2015

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â LEBEL FRANCOIS (Last) (First) (Middle) C/O ZIOPHARM ONCOLOGY, INC., NAVY YARD,Â ONE FIRST AVE., BLDG #34 (Street) BOSTON,Â MAÂ 02129 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 02/09/2015	3. Issuer Name and Ticker or Trading Symbol ZIOPHARM ONCOLOGY INC [ZIOP]	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Executive Vice President R&D	5. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
---	--	--	--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of			

Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 3

				Shares		or Indirect (I) (Instr. 5)	
Employee Stock Option (right to buy)	Â (1)	03/17/2023	Common Stock	45,000	\$ 5.71	D	Â
Employee Stock Option (right to buy)	Â (2)	06/26/2023	Common Stock	110,000	\$ 2.3	D	Â
Employee Stock Option (right to buy)	Â (3)	12/30/2023	Common Stock	150,000	\$ 4.34	D	Â
Employee Stock Option (right to buy)	Â (4)	12/30/2024	Common Stock	175,000	\$ 5.07	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LEBEL FRANCOIS C/O ZIOPHARM ONCOLOGY, INC., NAVY YARD ONE FIRST AVE., BLDG #34 BOSTON, MA 02129	Â	Â	Â Executive Vice President R&D	Â

Signatures

/s/ Francois
Lebel 02/17/2015

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option is vested with respect to 15,000 shares; the option vests with respect to the remaining 30,000 shares on 3/18/2015 and 3/18/2016.
- (2) The option is vested with respect to 36,667 shares; the option vests with respect to the remaining 73,333 shares on 6/27/2015 and 6/27/2016.
- (3) The option is vested with respect to 50,000 shares; the option vests with respect to the remaining 100,000 shares on 12/31/2015 and 12/31/2016.
- (4) The option vests in equal installments on each of the following dates: 12/31/2015, 12/31/2016 and 12/31/2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.